Theradaptive seeks to significantly improve patient outcomes by producing targeted therapeutics that can be used to coat implants, devices, and injectable carriers. Their proprietary protein-engineering platform aims to provide greater efficacy, safety, and ease of use across multiple clinical indications including orthopedics, immuno-oncology and dental.

“The promise of a new antibacterial technology that can fight infection without antibiotics, chemicals, or temporary coatings is truly transformational,” said Wayne Gattinella, CEO of DeBogy Molecular. “The possibilities of the DeBogy platform to improve the quality of life and reduce the cost of care for millions of people are enormous.”

“We are excited to introduce the Mix-n-Stain™ CF® Dye IgM Antibody Labeling Kits to the scientific community,” says Dr. Lori Roberts, Director of Bioscience at Biotium. “This technology provides a new and simple solution to the longstanding challenge of IgM conjugation. We believe these kits will provide researchers with more flexibility in panel design for immunofluorescence and flow cytometry.”

Dr. Jeremy Skillington, Chief Executive Officer of Poolbeg, commented: “The validation of the encapsulation process is a key step in the creation of a Phase I clinical trial ready oral vaccine candidate and Poolbeg is proud to lead the EncOVac Consortium. Delivering oral vaccines to the gut has the potential to revolutionise global protection against infectious disease. In contrast to intramuscular vaccines that generate systemic immunity, oral vaccines induce mucosal immunity, which can induce better protection against pathogens at the site of infection.”

AntiBKV has potential to be first- and best-in-class treatment representing the sole option for large and growing number of patients. Interim data expected by the end of 2023; on track to reach patients in 2025.